PDE4A

3',5'-cyclic-AMP phosphodiesterase 4A · P27815 · PDE4A on Sugi Atlas →

383,685 patent compounds predicted against PDE4A, 238,953 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Cilomilast (SCHEMBL26372)	1.00	19/20
Cilomilast (SCHEMBL27515)	1.00	19/20
Cilomilast (SCHEMBL27516)	1.00	19/20
Rolipram (SCHEMBL27930)	1.00	19/20
Cipamfylline (SCHEMBL26990)	1.00	13/20
Piclamilast (SCHEMBL26573)	1.00	10/20
Theophylline Anhydrous (SCHEMBL4915)	0.96	9/20
Theophylline Anhydrous (SCHEMBL5037)	0.81	9/20
Roflumilast (SCHEMBL19158)	1.00	8/20
SCHEMBL18250	0.56	7/20
Zardaverine (SCHEMBL13334)	1.00	6/20
SCHEMBL29488	0.45	6/20
SCHEMBL20867	0.51	5/20
SCHEMBL18247	0.47	5/20
SCHEMBL20866	0.40	5/20
1-Methylxanthine (SCHEMBL10996)	0.64	4/20
Guaifenesin (SCHEMBL20358)	0.52	4/20
SCHEMBL28454	0.40	4/20
Milrinone (SCHEMBL36947)	1.00	3/20
Milrinone (SCHEMBL36948)	0.75	3/20

Clinical trials — most relevant to PDE4A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis	PHASE4	COMPLETED
Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study	PHASE4	COMPLETED
Bosentan in Treatment of Pulmonary Arterial Hypertension	PHASE4	COMPLETED
Use of Sildenafil Citrate in Management of Mild Pre-eclampsia	PHASE2/PHASE3	UNKNOWN
Chronic Sildenafil Treatment in Heart Failure	PHASE3	COMPLETED
The Efficacy and Safety of Vardenafil in the Treatment of Pulmonary Arterial Hypertension	PHASE3	COMPLETED
Genetic Factors of Erectile Dysfunction Degree and Response to Tadalafil Treatment in Patients With Diabetes	PHASE3	RECRUITING
Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage	PHASE3	NOT_YET_RECRUITING
Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)	PHASE1/PHASE2	COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia	PHASE1/PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)	PHASE2	COMPLETED
Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old	PHASE2	ACTIVE_NOT_RECRUITING
Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease	PHASE2	COMPLETED
Safety Study of Sildenafil in Treatment of Cerebral Aneurysm Vasospasm	PHASE2	WITHDRAWN
PDE5 Inhibition for Obesity-Related Cardiometabolic Dysfunction	PHASE2	COMPLETED
Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients	PHASE1/PHASE2	COMPLETED
Effect of Tadalafil on Cerebral Large Arteries in Stroke	PHASE2	COMPLETED
Safety Study of the Effect of Scelectium Tortuosum (as Zembrin®)in Aged Normals	PHASE1	COMPLETED
PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram	PHASE1	COMPLETED
Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients	PHASE1	COMPLETED
Vitamin D Versus Sildenafil Citrate in Fetal Growth Restriction	PHASE1	COMPLETED
[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET	PHASE1	RECRUITING
Clinical Study for the Effectiveness of Roflumilast Treatment in COPD Greek Patients Based on Standard Clinical Practice.	nan	UNKNOWN
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis	nan	NOT_YET_RECRUITING
Silodosin, Tadalafil Alone vs. Silodosin Plus Tadalafil as MET for Lower Ureteric Stones	nan	COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Platelet and Tissue cAMP: Novel Biomarkers of Milrinone Efficacy in Children	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Sildenafil Citrate Added to Low Molecular Weight Heparin and Low Dose Aspirin in High-risk Pregnancy	nan	WITHDRAWN

Related proteins — ESM-2 sequence neighbours (a PDE4A binder may also engage these)

Protein	Name	Similarity
O89084	—	1.000	O89084 →
P54748	—	1.000	P54748 →
PDE4C	3',5'-cyclic-AMP phosphodiesterase 4C	0.997	landscape →
P14646	—	0.997	P14646 →
PDE4B	3',5'-cyclic-AMP phosphodiesterase 4B	0.996	landscape →
MAP3K13	Mitogen-activated protein kinase kinase kinase 13	0.994	landscape →
P14270	—	0.994	P14270 →
Q9UPV7	—	0.994	Q9UPV7 →
Q01063	—	0.993	Q01063 →
Q63553	—	0.993	Q63553 →
A7MBB4	—	0.993	A7MBB4 →
PDE4D	3',5'-cyclic-AMP phosphodiesterase 4D	0.991	landscape →
Q3ULB5	—	0.991	Q3ULB5 →
Q9H329	—	0.991	Q9H329 →
P10244	—	0.991	P10244 →
Q6EEF3	—	0.991	Q6EEF3 →
Q99PT9	—	0.990	Q99PT9 →
P46200	—	0.990	P46200 →
Q5R8X7	—	0.990	Q5R8X7 →
Q60700	—	0.990	Q60700 →
Q92539	—	0.990	Q92539 →
P12252	—	0.989	P12252 →
O43310	—	0.989	O43310 →
Q8TBC3	—	0.989	Q8TBC3 →
A3KMV1	—	0.989	A3KMV1 →
Q5R4R7	—	0.989	Q5R4R7 →
Q1HKZ5	—	0.989	Q1HKZ5 →
Q2TAC6	—	0.989	Q2TAC6 →
Q2PFD7	—	0.989	Q2PFD7 →
Q811P8	—	0.989	Q811P8 →